Risks

Negative interest coverage and a modest debt load versus peers can constrain financing flexibility if operating losses persist, even with stronger liquidity than many small-cap biotech peers.

A very long cash conversion cycle driven by extended payables and inventory build can pressure working-capital efficiency, though this is less punitive than for peers with tighter supplier terms.

Days sales outstanding remain elevated versus commercial-stage peers, which can delay cash realization and amplify volatility in a capital-intensive development model.

Limited free-cash-flow visibility versus profitable specialty pharma peers keeps valuation support more dependent on external funding and milestone timing, increasing downside sensitivity to execution slippage.

Opportunities

Net cash positioning and a current ratio above 2.6 provide more balance-sheet resilience than leveraged biotech peers, supporting longer operating runway through development cycles.

Liquidity metrics materially exceed many clinical-stage peers, which can improve negotiating leverage with partners and reduce near-term dilution risk if capital markets tighten.

A negative cash conversion cycle indicates supplier financing is offsetting working-capital needs, creating a relative advantage versus peers that must fund inventory and receivables more directly.

Low debt-to-equity versus broader healthcare peers preserves strategic flexibility for licensing, commercialization, or selective investment if pipeline catalysts improve.

Overall Score

ZENA’s stronger liquidity and low leverage versus peers support resilience, but negative interest coverage and working-capital inefficiency keep forward positioning only moderately attractive.